Stockscreener 앱 받기
350.78
0.08%
0.29
Penumbra Inc 주식(PEN)의 최신 뉴스
UnitedHealth Stock Slips Amid Medicare Investigation; Boston Scientific to Acquire Penumbra for $14.5B - Intellectia AI
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
Halper Sadeh LLC Encourages PEN, CVGW, AVO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
(PEN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
US-based Penumbra preliminary revenue up 22% Q4 2025 - Medical Buyer
Boston Scientific to acquire Penumbra for $14.5 billion By Investing.com - Investing.com Nigeria
RTW Biotech Opp.Boston Scientific to acquire Penumbra - Research Tree
Penumbra (PEN) Receives Neutral Rating with Raised Price Target by Citigroup | PEN Stock News - GuruFocus
PEN: Baird Downgrades Penumbra to 'Neutral', Raises Price Target - GuruFocus
PEN: Truist Securities Downgrades Penumbra to Hold | PEN Stock N - GuruFocus
Penumbra stock hits 52-week high at $321.47 By Investing.com - Investing.com Nigeria
Penumbra Inc. to be Sold to Boston Scientific for $374 per Share - Intellectia AI
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - Your Wyoming Link
Penumbra Announces Strong Preliminary Revenue Growth for 2025 - The Globe and Mail
Boston Scientific to acquire Penumbra in $14.5 billion deal - DOTmed
Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger - Insider Monkey
PEN Downgraded to Hold by Jefferies; Price Target Raised | PEN S - GuruFocus
Penumbra (PEN) Downgraded to Market Perform by Leerink Partners - GuruFocus
PEN Downgraded to Hold by Needham's Analyst Mike Matson | PEN St - GuruFocus
Needham & Company LLC Reaffirms "Hold" Rating for Penumbra (NYSE:PEN) - MarketBeat
Truist Securities Downgrades Penumbra to Hold From Buy, Adjusts PT to $374 From $370 - marketscreener.com
Analyst Expectations For Penumbra's Future - Benzinga
Citigroup Downgrades Penumbra to Neutral From Buy, Adjusts Price Target to $374 From $350 - marketscreener.com
Boston Scientific: Adding Another Growth Engine With Penumbra (NYSE:BSX) - Seeking Alpha
Boston Scientific announces agreement to acquire Penumbra, Inc. - Med-Tech Insights
This JM Smucker Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
Published on: 2026-01-16 16:12:24 - baoquankhu1.vn
Truist Securities downgrades Penumbra stock to Hold following Boston Scientific acquisition - Investing.com Australia
Boston Scientific to acquire Penumbra for $14.5 billion - Investing.com India
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results - BioSpace
RTW Biotech Opportunities Portfolio Company Penumbra To Be Acquired By Boston Scientific - DirectorsTalk Interviews
Penumbra reports preliminary Q4 revenue growth of over 21% By Investing.com - Investing.com Nigeria
Boston Scientific to acquire Penumbra in $14.5 billion deal By Investing.com - Investing.com Nigeria
Boston Scientific Set to Acquire Penumbra in $14.5 Billion Deal to Expand Vascular Therapy Offerings - Hoodline
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead - TechStock²
Penumbra (PEN) Downgraded to Market Perform by William Blair | P - GuruFocus
Boston Scientific to acquire Penumbra for portfolio of vascular treatments - MLex
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next - TechStock²
[425] Penumbra Inc Business Combination Communication | PEN SEC FilingForm 425 - Stock Titan
Penumbra’s Stock Set to Surge Amid New Price Targets - timothysykes.com
Boston Sci swings for the fences with $14.5B Penumbra buy - BioWorld MedTech
Fenwick Represents Perella Weinberg Partners in Penumbra's $14.5B Acquisition by Boston Scientific - fenwick.com
One of Alameda's largest companies agrees to be acquired for $14.5 billion - The Business Journals
Penumbra’s Bright Future: Analysts Raise Price Targets as MedTech Sector Rebounds - StocksToTrade
Penumbra (PEN) Downgraded by Wells Fargo to Equal-Weight | PEN S - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN) - PR Newswire
Penumbra (PEN) Shares Surge Nearly 12% - GuruFocus
Penumbra Shares Buoyed by Analyst Upgrades and Market Positivity - timothysykes.com
Penumbra (PEN) Projects 67.1% Gross Margin for Fiscal Year 2025 - GuruFocus
Boston Scientific Catches Lightning in a Bottle with Penumbra - Medical Device and Diagnostic industry
Why Penumbra (PEN) Stock Is Trading Up Today - Finviz
JPM26: Boston Scientific acquires Penumbra in $14.5bn deal - Yahoo Finance
A&O Shearman advises Boston Scientific Corporation on its USD15 billion proposed acquisition of Penumbra, Inc. - A&O Shearman
Penumbra up 12% on Boston Scientific's $14.5B buyout - breakingthenews.net
Penumbra’s Stock Jumps Amid Strong Market Outlook - StocksToTrade
Boston Scientific to acquire Penumbra in $14.5B deal - Proactive financial news
Evercore ISI’s Optimism Sparks Penumbra Price Target Rise - timothysykes.com
The Thrombectomy Titan: Boston Scientific Shakes MedTech with $14.5 Billion Penumbra Acquisition - The Chronicle-Journal
Boston Scientific stock rises as Stifel praises Penumbra acquisition - Investing.com India
Shareholder Alert: The Ademi Firm investigates whether Penumbra, Inc. is obtaining a Fair Price for its Public Shareholders - The Malaysian Reserve
Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal - Reuters
Boston Scientific pays $14.5B for California medical device company - The Business Journals
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
0.42%
1.96%
자본화:
|
볼륨(24시간):